Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1992 Aug 15;89(16):7777–7781. doi: 10.1073/pnas.89.16.7777

Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model.

R J Natuk 1, P K Chanda 1, M D Lubeck 1, A R Davis 1, J Wilhelm 1, R Hjorth 1, M S Wade 1, B M Bhat 1, S Mizutani 1, S Lee 1, et al.
PMCID: PMC49794  PMID: 1502197

Abstract

Recombinant human adenoviruses (Ads) (types 4, 5, and 7) expressing the HIV-1 envelope membrane glycoprotein (gp160) were tested for immunogenicity in the dog. Administration of recombinant Ad7-env by intratracheal inoculation resulted in a low serum antibody response to gp160, which developed over several weeks. A strong neutralizing antibody response to the Ad7 vector developed within 1 week of infection. A subsequent booster inoculation 12 weeks later with the heterotypic Ad4-env recombinant virus resulted in significantly enhanced humoral responses directed at the envelope antigen, as measured by both ELISA and Western blot analysis as well as high-titer type-specific neutralizing antibodies, with some animals achieving neutralization titers approaching 1000. Recombinant HIV envelope glycoprotein derived from Ad-HIV-infected cell cultures was used as a subunit booster injection for dogs that had previously received sequential immunizations with heterotypic recombinant Ads. Significant immune responses against the envelope developed as measured by ELISA, Western blot analysis, and neutralization assays. These data indicate that live recombinant Ad-HIV vaccines are capable of inducing high-titer type-specific neutralizing antibodies to gp160 in vivo. Recombinant HIV envelope glycoprotein subunit vaccines, prepared from Ad-env-infected cells, are capable of boosting these responses.

Full text

PDF
7777

Images in this article

7778Image
on p.7778
7780Image
on p.7780

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990 Jun 14;345(6276):622–625. doi: 10.1038/345622a0. [DOI] [PubMed] [Google Scholar]
  2. Berman P. W., Groopman J. E., Gregory T., Clapham P. R., Weiss R. A., Ferriani R., Riddle L., Shimasaki C., Lucas C., Lasky L. A. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5200–5204. doi: 10.1073/pnas.85.14.5200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carrow E. W., Vujcic L. K., Glass W. L., Seamon K. B., Rastogi S. C., Hendry R. M., Boulos R., Nzila N., Quinnan G. V., Jr High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. AIDS Res Hum Retroviruses. 1991 Oct;7(10):831–838. doi: 10.1089/aid.1991.7.831. [DOI] [PubMed] [Google Scholar]
  4. Chanda P. K., Natuk R. J., Mason B. B., Bhat B. M., Greenberg L., Dheer S. K., Molnar-Kimber K. L., Mizutani S., Lubeck M. D., Davis A. R. High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants. Virology. 1990 Apr;175(2):535–547. doi: 10.1016/0042-6822(90)90438-w. [DOI] [PubMed] [Google Scholar]
  5. Cheingsong-Popov R., Weiss R. A., Dalgleish A., Tedder R. S., Shanson D. C., Jeffries D. J., Ferns R. B., Briggs E. M., Weller I. V., Mitton S. Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain. Lancet. 1984 Sep 1;2(8401):477–480. doi: 10.1016/s0140-6736(84)92562-5. [DOI] [PubMed] [Google Scholar]
  6. Chengalvala M., Lubeck M. D., Davis A. R., Mizutani S., Molnar-Kimber K., Morin J., Hung P. P. Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs. Vaccine. 1991 Jul;9(7):485–490. doi: 10.1016/0264-410x(91)90033-3. [DOI] [PubMed] [Google Scholar]
  7. Davis A. R., Kostek B., Mason B. B., Hsiao C. L., Morin J., Dheer S. K., Hung P. P. Expression of hepatitis B surface antigen with a recombinant adenovirus. Proc Natl Acad Sci U S A. 1985 Nov;82(22):7560–7564. doi: 10.1073/pnas.82.22.7560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dewar R. L., Natarajan V., Vasudevachari M. B., Salzman N. P. Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus. J Virol. 1989 Jan;63(1):129–136. doi: 10.1128/jvi.63.1.129-136.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fauci A. S., Gallo R. C., Koenig S., Salk J., Purcell R. H. NIH conference. Development and evaluation of a vaccine for human immunodeficiency virus (HIV) infection. Ann Intern Med. 1989 Mar 1;110(5):373–385. doi: 10.7326/0003-4819-110-5-373. [DOI] [PubMed] [Google Scholar]
  10. Gallo R. C., Salahuddin S. Z., Popovic M., Shearer G. M., Kaplan M., Haynes B. F., Palker T. J., Redfield R., Oleske J., Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500–503. doi: 10.1126/science.6200936. [DOI] [PubMed] [Google Scholar]
  11. Girard M. P., Eichberg J. W. Progress in the development of HIV vaccines. AIDS. 1990;4 (Suppl 1):S143–S150. [PubMed] [Google Scholar]
  12. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol. 1967 Jun 14;26(2):365–369. doi: 10.1016/0022-2836(67)90307-5. [DOI] [PubMed] [Google Scholar]
  13. Hu S. L., Fultz P. N., McClure H. M., Eichberg J. W., Thomas E. K., Zarling J., Singhal M. C., Kosowski S. G., Swenson R. B., Anderson D. C. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature. 1987 Aug 20;328(6132):721–723. doi: 10.1038/328721a0. [DOI] [PubMed] [Google Scholar]
  14. Javaherian K., Langlois A. J., LaRosa G. J., Profy A. T., Bolognesi D. P., Herlihy W. C., Putney S. D., Matthews T. J. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science. 1990 Dec 14;250(4987):1590–1593. doi: 10.1126/science.1703322. [DOI] [PubMed] [Google Scholar]
  15. Lubeck M. D., Davis A. R., Chengalvala M., Natuk R. J., Morin J. E., Molnar-Kimber K., Mason B. B., Bhat B. M., Mizutani S., Hung P. P. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6763–6767. doi: 10.1073/pnas.86.17.6763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Matsushita S., Robert-Guroff M., Rusche J., Koito A., Hattori T., Hoshino H., Javaherian K., Takatsuki K., Putney S. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol. 1988 Jun;62(6):2107–2114. doi: 10.1128/jvi.62.6.2107-2114.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Popovic M., Sarngadharan M. G., Read E., Gallo R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984 May 4;224(4648):497–500. doi: 10.1126/science.6200935. [DOI] [PubMed] [Google Scholar]
  18. Pyle S. W., Dubois G. C., Robey W. G., Bess J. W., Jr, Fischinger P. J., Arthur L. O. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF. J Virol. 1988 Jul;62(7):2258–2264. doi: 10.1128/jvi.62.7.2258-2264.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Robert-Guroff M., Aldrich K., Muldoon R., Stern T. L., Bansal G. P., Matthews T. J., Markham P. D., Gallo R. C., Franchini G. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. J Virol. 1992 Jun;66(6):3602–3608. doi: 10.1128/jvi.66.6.3602-3608.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rusche J. R., Javaherian K., McDanal C., Petro J., Lynn D. L., Grimaila R., Langlois A., Gallo R. C., Arthur L. O., Fischinger P. J. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A. 1988 May;85(9):3198–3202. doi: 10.1073/pnas.85.9.3198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Schneider M., Graham F. L., Prevec L. Expression of the glycoprotein of vesicular stomatitis virus by infectious adenovirus vectors. J Gen Virol. 1989 Feb;70(Pt 2):417–427. doi: 10.1099/0022-1317-70-2-417. [DOI] [PubMed] [Google Scholar]
  22. Shaw G. M., Hahn B. H., Arya S. K., Groopman J. E., Gallo R. C., Wong-Staal F. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science. 1984 Dec 7;226(4679):1165–1171. doi: 10.1126/science.6095449. [DOI] [PubMed] [Google Scholar]
  23. Zagury D., Bernard J., Cheynier R., Desportes I., Leonard R., Fouchard M., Reveil B., Ittele D., Lurhuma Z., Mbayo K. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature. 1988 Apr 21;332(6166):728–731. doi: 10.1038/332728a0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES